CoChat
Sign Up
Cited by 62Advancements in Transdermal Drug DeliveryDermatology and Skin DiseasesSkin Protection and Aging

Topical hesperidin improves epidermal permeability barrier function and epidermal differentiation in normal murine skin

Open access
Hou, Maihua, Man, Mona, Man, Wenyan, Zhu, Wenyuan, Hupe, Melanie, Park, Kyungho, Crumrine, Debra, Elias, Peter M. +1 more·2012·Experimental Dermatology
DOI 10.1111/j.1600-0625.2012.01455.xPMC PMC3335754
Open this paper in CoChat — free account

Abstract

Abstract: Orange peel extract appears to exhibit beneficial effects on skin whitening, inflammation, UVB protection, as well as keratinocyte proliferation. In the present study, we determine whether topical hesperidin influences epidermal permeability barrier function and its underlying mechanisms. Hairless mice were treated topically with 2% hesperidin or 70% ethanol alone twice daily for 6 days. At the end of treatment, basal transepidermal water loss (TEWL) was measured 2 and 4 h post barrier disruption. Epidermal proliferation and differentiation were evaluated by immunohistochemical staining and Western blot analysis. Additionally, lamellar body density and secretion were assessed by electron microscopy. Although there were no significant differences in basal barrier function, in comparison with control animals, topical hesperidin significantly accelerated barrier recovery at both 2 and 4 h after acute barrier abrogation. Enhanced barrier function in hesperidin‐treated skin correlated with stimulation of both epidermal proliferation and differentiation, as well as enhanced lamellar body secretion. These results indicate that topical hesperidin enhances epidermal permeability barrier homeostasis at least in part due to stimulation of epidermal proliferation, differentiation, as well as lamellar body secretion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-0625.2012.01455.x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 49

  1. [1]Park HJ Kim MJ Ha E Chung JH Phytomedicine 2008 15 147 51 17897817
  2. [2]Lee CJ Wilson L Jordan MA Nguyen V Tang J Smiyun G Phytother Res 2010 24 S15 9 19548283
  3. [3]Jin YR Han XH Zhang YH J Cell Biochem 2008 104 1 14 17979132
  4. [4]Zheng Q Hirose Y Yoshimi N J Cancer Res Clin Oncol 2002 128 539 46 12384797 PMC12164404
  5. [5]So FV Guthrie N Chambers AF Moussa M Carroll KK Nutr Cancer 1996 26 167 81 8875554
  6. [6]Koyuncu H Berkarda B Baykut F Anticancer Res 1999 19 3237 41 10652617
  7. [7]Berkarda B Koyuncu H Soybir G Baykut F Res Exp Med (Berl) 1998 198 93 9 9782529
  8. [8]Tanaka T Kohno H Murakami M Int J Cancer 2000 88 146 50 10962453
  9. [9]Li R Li J Cai L Hu CM Zhang L J Pharm Pharmacol 2008 60 221 8 18237470
  10. [10]Kaur G Tirkey N Chopra K Toxicology 2006 226 152 60 16919860
  11. [11]Kobayashi S Tanabe S Int J Mol Med 2006 17 511 5 16465400
  12. [12]Trzeciakiewicz A Habauzit V Mercier S J Nutr Biochem 2010 21 424 31 19427185
  13. [14]Aranganathan S Selvam JP Nalini N J Pharm Pharmacol 2008 60 1385 92 18812032
  14. [15]Cvetnić Z Vladimir-Knezević S Acta Pharm 2004 54 243 50 15610620
  15. [16]Panasiak W Wleklik M Oraczewska A Luczak M Acta Microbiol Pol 1989 38 185 8 2482663
  16. [17]Mandalari G Bennett RN Bisignano G J Appl Microbiol 2007 103 2056 64 18045389
  17. [18]Cvetnić Z Vladimir-Knezević S Acta Pharm 2004 54 243 50 15610620
  18. [19]Kawaguchi K Kikuchi S Hasunuma R Maruyama H Yoshikawa T Kumazawa Y Biol Pharm Bull 2004 27 679 83 15133244
  19. [20]Kaur G Tirkey N Bharrhan S Chanana V Rishi P Chopra K Clin Exp Immunol 2006 145 313 21 16879252 PMC1809677
  20. [21]Tirkey N Pilkhwal S Kuhad A Chopra K BMC Pharmacol 2005 5 2 15683547 PMC549532
  21. [22]Pradeep K Park SH Ko KC Eur J Pharmacol 2008 587 273 80 18485345
  22. [23]Nazari M Ghorbani A Hekmat-Doost A Jeddi-Tehrani M Zand H Eur J Pharmacol 2011 650 526 33 21044621
  23. [24]Ghorbani A Nazari M Jeddi-Tehrani M Zand H Eur J Nutr 29 3 2011 DOI 10.1007/s00394-011-0187-2 21445621 · DOI
  24. [25]Zhu W Gao J J Invest Dermatol Symp Proc 2008 13 20 4 18369335
  25. [26]Zhang C Lu Y Tao L Tao X Su X Wei D J Enzyme Inhib Med Chem 2007 22 83 90 17373552
  26. [27]Tsai YH Lee KF Huang YB Huang CT Wu PC Int J Pharm 2010 388 257 62 20060453
  27. [28]Thiele JJ Skin Pharmacol Appl Skin Physiol 2001 14 Suppl 1 87 91 11509912
  28. [29]Mao-Qiang M Fowler AJ Schmuth M J Invest Dermatol 2004 123 305 12 15245430
  29. [30]Man M Hupe M Mackenzie D Exp Dermatol 2011 20 285 8 21323748 PMC4548955
  30. [31]Demerjian M Man MQ Choi EH Exp Dermatol 2006 15 154 60 16480422
  31. [32]Man MQ Shi Y Man M Exp Dermatol 2008 17 681 7 18341576 PMC2843409
  32. [33]Feingold KR Schmuth M Elias PM J Invest Dermatol 2007 127 1574 6 17568800
  33. [34]Al-Ashaal HA El-Sheltawy ST Pharm Biol 2011 49 276 82 21323480
  34. [35]Jain M Parmar HS Inflamm Res 2011 60 483 91 21181230
  35. [36]El-Sayed el-SM Abo-Salem OM Abd-Ellah MF Abd-Alla GM J Biochem Mol Toxicol 2008 22 268 73 18752313
  36. [37]De Pascale MC Bassi AM Patrone V Villacorta L Azzi A Zingg JM Arch Biochem Biophys 2006 447 97 106 16530159
  37. [38]Kuramoto N Takizawa T Takizawa T J Clin Invest 2002 109 243 50 11805136 PMC150837
  38. [39]Patrick BA Gong X Jaiswal AK Oncogene 2011 30 1098 107 21042282 PMC3307144
  39. [40]Manca S Magrelli A Cialfi S Exp Dermatol 6 8 2011 doi: 10.1111/j.1600-0625.2011.01359.x 21913998 · DOI
  40. [41]Aberg KM Racz E Behne MJ Mauro TM J Invest Dermatol 2007 127 1973 9 17392835
  41. [42]Scharschmidt TC Man MQ Hatano Y J Allergy Clin Immunol 2009 124 496 506 19733297 PMC2881668
  42. [43]Angelova-Fischer I Mannheimer AC Hinder A Exp Dermatol 2011 20 351 6 21410766
  43. [44]Magnaldo T Bernerd F Asselineau D Darmon M Differentiation 1992 49 39 46 1378029
  44. [45]Wu Z Hansmann B Meyer-Hoffert U Gläser R Schröder JM PLoS One 2009 4 e5227 19384417 PMC2668185
  45. [46]Banks-Schlegel S Green H J Cell Biol 1981 90 732 7 6895225 PMC2111911
  46. [47]Niderla-Bielińska J Moskalewski S Folia Histochem Cytobiol 2011 49 335 43 21744336
  47. [48]Kömüves LG Hanley K Lefebvre AM J Invest Dermatol 2000 115 353 60 10951268
  48. [49]Oudshoorn MH Rissmann R van der Coelen D Hennink WE Ponec M Bouwstra JA Exp Dermatol 2009 18 178 84 18684123
  49. [50]Aschoff R Schwanebeck U Bräutigam M Meurer M Exp Dermatol 2009 18 24 9 18637133

Cited by

Sorted by citations

Authors
Hou, M., Man, M., Man, W., Zhu, W., Hupe, M., Park, K., Crumrine, D., Elias, P. M., & Man, M.
Affiliations
University of California, San Francisco (US)
Corresponding author
Man, Mao‐Qiang
ORCID
Elias, Peter M.
Venue
Experimental Dermatology
Publisher
Wiley
Published
2012-04-18
Volume
21
Issue
5
Pages
337-340
ISSN
  • 0906-6705 (ISSN-L)
  • 1600-0625
DOI
10.1111/j.1600-0625.2012.01455.x
PMC
PMC3335754
OpenAlex
W1762431693
Cited by
62
References
0
Citations by year
2026: 5 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 8 · 2013: 4 · 2012: 1
FWCI
4.16
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Experimental Dermatology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Foundation for the National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-19098, R01AR019098)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Keywords
hesperidin, epidermal permeability barrier, transepidermal water loss, epidermal differentiation, keratinocyte proliferation, barrier recovery, orange peel extract, topical application, hairless mice
MeSH terms
Epidermal Cells, Administration, Topical, Animals, Biopsy, Cell Differentiation, Cell Membrane Permeability, Dose-Response Relationship, Drug, Epidermis, Female, Hesperidin, Homeostasis, Mice, Hairless, Models, Animal, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review